Compare OPXS & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPXS | BNR |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | China |
| Employees | 72 | N/A |
| Industry | Electronic Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 99.7M |
| IPO Year | 2009 | 2019 |
| Metric | OPXS | BNR |
|---|---|---|
| Price | $10.13 | $10.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.10 | N/A |
| AVG Volume (30 Days) | ★ 31.7K | 11.8K |
| Earning Date | 05-11-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.55 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $24,530,000.00 | N/A |
| Revenue This Year | $39.17 | $111.65 |
| Revenue Next Year | $0.53 | N/A |
| P/E Ratio | $25.01 | ★ N/A |
| Revenue Growth | ★ 17.63 | N/A |
| 52 Week Low | $9.04 | $6.79 |
| 52 Week High | $17.76 | $41.72 |
| Indicator | OPXS | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 52.67 |
| Support Level | $10.14 | $8.83 |
| Resistance Level | $14.00 | $10.72 |
| Average True Range (ATR) | 0.52 | 0.76 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 48.75 | 53.02 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.